Studies hereditary transthyretin amyloidosis and how it progresses in patients
Observes adults over 18 with an inherited TTR variant through clinical checks and tests.
Plain-language title generated from the registry record
Registry title: Comprehensive Program for Hereditary Transthyretin Amyloidosis
Key facts
- Where
- Canuelas, ArgentinaSee the site
Where in Argentina
- Hospital Cuenca Alta de CañuelasCanuelas, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital de Alta Complejidad en Red
- Trial code
- NCT07213297
- Record updated
- 24 March 2026
- Original description
The Comprehensive Program for Hereditary Transthyretin Amyloidosis describes a prospective observational study focused on understanding hereditary transthyretin amyloidosis (ATTR), a progressive and potentially fatal condition marked by amyloid fibril deposits impacting multiple organs. The trial aims to characterize patient phenotypes, investigate factors affecting disease progression, and identify minimum criteria for disease onset. Conducted at Néstor Kirchner Hospital, the trial enrolls participants over 18 years old with confirmed pathogenic TTR variants. It includes thorough evaluations such as genetic testing sponsored by pharmaceutical companies, clinical assessments, and diverse diagnostic tests.Read full original descriptionShow less
Comprehensive Program for Hereditary Transthyretin Amyloidosis
The Comprehensive Program for Hereditary Transthyretin Amyloidosis describes a prospective observational study focused on understanding hereditary transthyretin amyloidosis (ATTR), a progressive and potentially fatal condition marked by amyloid fibril deposits impacting multiple organs. The trial aims to characterize patient phenotypes, investigate factors affecting disease progression, and identify minimum criteria for disease onset. Conducted at Néstor Kirchner Hospital, the trial enrolls participants over 18 years old with confirmed pathogenic TTR variants. It includes thorough evaluations such as genetic testing sponsored by pharmaceutical companies, clinical assessments, and diverse diagnostic tests.
Inclusion: -Participants with a pathogenic variant of the TTR gene (Hereditary Amyloidosis).
Exclusion: wild-type TTR amyloidosis.